Source-grounded facts extracted from Ultragenyx Pharmaceutical Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Ultragenyx Pharmaceutical Inc. reported the quarter ended March 31, 2026 results: revenue $136 million. Guidance reaffirmed.
“Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D”
Ultragenyx Pharmaceutical Inc. announced a restructuring with charges of approximately $50 million in total restructuring and restructuring-related charges affecting across the Company (10% workforce reduction of approximately 130 employees).
“the Company is implementing a 10% workforce reduction of approximately 130 employees across the Company (the “RIF”). The Company began notifying affected employees on February 12, 2026, and expects this RIF to be substantially completed in the first half of 2026. The Company estimates that it will incur approximately $50 million in total restructuring and restructuring-related charges”
Ultragenyx Pharmaceutical Inc. reported quarter ended March 31, 2024 results: revenue $109 million, net income net loss of $171 million, or $2.03 per share basic and diluted, EPS $2.03 per share basic and diluted. Guidance reaffirmed.
“Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of”
Ultragenyx Pharmaceutical Inc. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).
“On February 15, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2023 and the year ended December 31, 2023”
Ultragenyx Pharmaceutical Inc. reported fiscal year 2024 results: revenue $500 million to $530 million. Guidance initiated.
“2024 expected Total Revenue guidance between $500 million to $530 million”
Ultragenyx Pharmaceutical Inc. reported fiscal year 2023 results: revenue $430 million to $435 million.
“Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $ 325 million to $330 million and Dojolvi® revenue of $70 million to $71 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.